BioNTech SE BNTX shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook.
BioNTech reported first-quarter revenue of 6.37 billion euros ($6.72 billion), which was up from €2.05 billion year-over-year. The company reported quarterly earnings of €14.24 per share, up from earnings of €4.39 per share, year-over-year.
"As a result of an increased order volume initially placed in late 2021 following the then emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance we issued a few months ago," said Jens Holstein, CFO of BioNTech.
BioNTech reiterated its previously issued 2022 expectations, which includes €13 billion to €17 billion in estimated COVID-19 vaccines revenues.
See Also: Why Palantir Technologies Shares Are Diving
BNTX 52-Week Range: $121.32 - $464
The stock was up 4.95% at $142.91 at time of publication.
Photo: courtesy of BioNTech.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
